Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the […]